Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

• Status: Unknown status
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Betta Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co.,Ltd.

Criteria

Inclusion Criteria:

• The patients present with operable stage IIA-IIIA (N0-1) lung adenocarcinoma with 19 or 21 exon mutation

• The patients have no history of anti-cancer therapies including chemotherapy, radiation therapy

• The patients' Eastern Cooperative Oncology Group scores are ≤ 0-1

• The patients signed the written informed consent

Exclusion Criteria:

• Patients with unresected tumor

• Wild EGFR type

• Allergic to the study drug

• Patients have severe non-cancerous diseases

• Patients are undergoing current administration of anti-cancer therapies, or are attending some other clinical trials